Schedule of Events: 2016 Treatment Center Investment & Valuation Retreat

Welcome and Opening Plenary - Federal Policy Update: Where We Are and Where We Need to Go

Carol McDaid, Principal, Capitol Decisions, Inc.

This presentation will provide an overview of key laws and regulations affecting addiction treatment and recovery such as the Mental Health Parity and Addiction Equity Act (MHPAEA), Affordable Care Act (ACA), the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), and other Department of Health and Human Services (HHS) regulations affecting access to addiction treatment as well as the recently passed Comprehensive Addiction and Recovery Act (CARA). The status of implementation and enforcement of these laws will also be provided.

Recommendations for more timely implementation and enforcement of these laws will be provided as well as trends the presenter sees that are occurring or are likely to occur because of the rapid transformation underway in the addiction treatment and recovery industry.

Sponsored by Vertess

Breakfast and Plenary Session

Practical Considerations for Buyers and Sellers in the SUD Space

Rob Waggener, Vice President, Addiction Services Division, Universal Health Services

The presentation will cover practical information for program owners/operators who are considering or questioning whether or not to take their program to market in the current frothy environment. Rob will also cover factors for buyers to consider when reviewing programs that enter the market. In so doing, Rob hopes to better inform both sides of current relevant factors in the M&A market.

Breakfast Sponsored by SAS Group

Current Trends in Addictions and Substance Abuse Mergers & Acquisitions

Dexter W. Braff, MBA, President, The Braff Group

2015 was another record breaking year in M&A for addiction treatment facilities, but the climate is anything but status quo. While there were the breakout segments during the year, did any falter? What is the current thinking as buyers continue to struggle with the trend toward in-network contracts? How has the predicted shift to lower-cost, community-based services progressed? And how has the interplay of all these factors impacted acquisition demand and valuation? The answers to these questions, and more, will provide important context for buyers and sellers alike.

"Crossing the Finish Line" - Key Factors for Making a Transaction a Success

Dave Johnson , President, Behavioral Health Division, Alanco Behavioral Health

Successful integration-the key to avoiding the risks of a merger or acquisition and to realizing its potential value-is always a challenge. And it is complicated by the simple fact that no two deals should be integrated in the same way, with the same priorities, or under exactly the same timetable. The presentation will discuss the essential guidelines can make the task far more manageable and lead to the right outcome:

Lunch and Plenary Session

Panel Discussion: Business Ethics in Behavioral Healthcare Delivery and Investment

Ethics Panelists:

Daniel J. Gemp, President, CEO, Dreamscape

Bobby Ferguson, Director, Founder, Jaywalker Lodge

Cory Mertz, M&AMI, Managing Partner, Mertz Taggart

Kathy Steadman, Attorney, Coppersmith Brockelman

Moderator:

Doug Edwards, Director, Institute for the Advancement of Behavioral Healthcare

As behavioral healthcare has become more mainstream, new business opportunities have developed. With attractive margins and a very wide market, addiction treatment in particular is attracting new entrants as well as stimulating growth among established players. Yet with this rapid change has come questions about the business ethics involved in the delivery of behavioral healthcare. Although some issues such as patient brokering are universally condemned, other issues are not so black and white. Join Behavioral Healthcare Editor in Chief Julie Miller for a panel discussion on ethics in behavioral healthcare business to explore these issues.

Upon attending this session attendees will be able to:

Articulate current ethical challenges facing owners, operations, and investors
Understand the complex interaction of marketing, reimbursement, investment, and evidence-based care delivery in addiction treatment
Describe resources available for confronting ethical issues

Sponsored by Mertz Taggart , Dreamscape Marketing, Billing Solutions

Being The Big Picture: Integrating Best Practices While Building Remarkable Value In Treatment Services

Tom Schramski, PhD, CMAA, President/Managing Partner, Vertess

In today’s dynamic treatment services marketplace the focus has been increasingly on the events of mergers and acquisitions, which is a misplaced emphasis. This presentation will focus on the integration of best clinical and management practices, how these behaviors are translated into observable operational success that drive value, and how to implement them in a practical manner as part of a pre-transaction strategy to build value in your treatment organization. The presentation will include specific examples and opportunities for examining implementation options.

Strategic vs. Private Equity: Who Will Be My Buyer, And Why Does It Matter Now?

Cory Mertz, M&AMI, Managing Partner, Mertz Taggart

Kevin Taggart, Managing Partner, Mertz Taggart

The behavioral health buyer universe is growing. As deal announcements continue to hit the newswires, two types of buyers stand out as most noteworthy: "strategic" buyers and “financial” buyers. Treatment operators are asking themselves, "What’s the difference?” and “Why does it matter to me?" In this session, attendees will explore the differences between these two types of buyers, including:

A private equity primer
Typical deal structures for each, with case study examples
How each meet different seller objectives
An explanation of the strategic/financial hybrid buyer
How to prepare yourself and your treatment center for an eventual transaction with each

Breakfast Plenary - Valuation of Treatment Systems: Why We Need to Show Clinical Value More Than Ever

Deni Carise, Ph.D. ,Chief Clinical Officer, Recovery Centers of America; Adjunct Clinical Professor, University of Pennsylvania

Getting your program ready for buyers? Now or in the future? How do you show your value? Sure – a great daily census and a good bottom line is where you must start from, but beyond that – what gives your program ongoing value? What makes your program different from any other program? This presentation will cover the development, implementation and measurement of effective clinical care programming in substance abuse treatment. It will focus on how to identify and select from among a wide array of practices with substantial scientific proof of effectiveness, how to implement them with fidelity and how to showcase your results. You will also leave with a list of the top 10 things to look for when evaluating a treatment program.

Breakfast Sponsored by BDO Consulting

Real Estate Selection

Josh Lannon, Founder/CEO, Warriors Heart

Described as “a driven person with out of the box insights,” Josh Lannon has successfully built and operated Journey Healing Centers, a private drug and alcohol treatment center. JHC grew to six locations with 100 team members and in late 2013, Elements Behavioral Health, a leading nationwide provider, acquired JHC. When exiting JHC, the Lannon's (he and his wife) maintained the real estate and leased the properties back to EBH. Lannon will candidly speak about what worked and what he would do differently.

Lunch and Master Class

Insurance Billing and Patient Financial Responsibility

John A. Mills, Partner, Nelson Hardiman

Pete Nielsen, CADC II, Chief Executive Officer, California Consortium of Addiction Programs and Professionals (CCAPP)

This Master Class is segmented into two parts:

Part 1: Insurance companies’ are increasingly conducting reviews of behavioral health and substance abuse treatment program providers and are looking for cases of fraud and abuse. Their special investigation units are demanding the recoupment of fees paid to such programs based on lack of licensure, certification, and accreditation, questions regarding the appropriateness of claims, and questions regarding the adequacy of documentation for clinical services. What are the key issues insurance companies are raising to demand recoupment of fees from substance abuse treatment programs? What can programs do to prevent such inquiries?

Part 2: Insurance companies expect drug treatment programs to collect money from patients for their financial responsibility under insurance contracts, including deductibles, copays, and coinsurance. In many cases, patients plagued by addiction do not have the financial ability to pay for the high cost of programs. Often, treatment centers provide ‘program scholarships’ or waive a patient’s financial responsibility altogether. However, insurance companies regard this practice as fraudulent. How can drug treatment programs reduce the cost of programs for those with limited financial means?

Schedule of EVents

Monday, December 5, 2016

Tuesday, December 6, 2016

Wednesday, December 7, 2016

Founded and Produced by the Publishers of

Founded and Produced by the Publishers of

Association Partners

Schedule of EVents

Monday, December 5, 2016

Tuesday, December 6, 2016

Wednesday, December 7, 2016

Share on social:

Founded and Produced by the Publishers of

Founded and Produced by the Publishers of

Association Partners